Renaissance Capital logo

NVET News

US IPO Weekly Recap: Yield takes the field as healthcare IPOs need a lifeline

Ten deals were on the IPO calendar to price this past week, but only three made it through as seven health care IPOs delayed going public. The year's first energy IPO...read more

Nexvet Biopharma prices IPO at $10, well below the range

Nexvet Biopharma, which is developing biologics for the treatment of pain and inflammation in cats and dogs, raised $40 million by offering 4.0 million shares at $10.00, well below the $13 to $16 range. Nexvet Biopharma will list on the NASDAQ under the symbol...read more

Week ahead: IPO market set for another surge in the health care sector with 10 IPOs

Ten IPOs are on the IPO calendar to raise $1.4 billion, led by an $800 million offering of natural gas pipelines. The MLP is joined by a government-focused REIT as the...read more

Paining cats and dogs: Nexvet sets terms for $58 million IPO

Nexvet, which is developing biologics for the treatment of pain and inflammation in cats and dogs, announced terms for its IPO on Monday. The Dublin, Ireland-based company plans to raise $58 million by offering 4.0 million shares at a price range of $13 to $16....read more